NASDAQ:VINC Vincerx Pharma (VINC) Stock Price, News & Analysis $0.72 -0.03 (-3.33%) (As of 12:25 PM ET) Add Compare Share Share Today's Range$0.73▼$0.7950-Day Range$0.57▼$0.9352-Week Range$0.57▼$9.37Volume44,410 shsAverage Volume888,463 shsMarket Capitalization$21.41 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Vincerx Pharma alerts: Email Address Vincerx Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside566.7% Upside$5.00 Price TargetShort InterestHealthy1.47% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.62) to ($0.48) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.43 out of 5 starsMedical Sector329th out of 896 stocksPharmaceutical Preparations Industry153rd out of 424 stocks 3.5 Analyst's Opinion Consensus RatingVincerx Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageVincerx Pharma has only been the subject of 1 research reports in the past 90 days.Read more about Vincerx Pharma's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.47% of the outstanding shares of Vincerx Pharma have been sold short.Short Interest Ratio / Days to CoverVincerx Pharma has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vincerx Pharma has recently decreased by 29.27%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldVincerx Pharma does not currently pay a dividend.Dividend GrowthVincerx Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VINC. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 1 people have searched for VINC on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Vincerx Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vincerx Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders22.90% of the stock of Vincerx Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions44.02% of the stock of Vincerx Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vincerx Pharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Vincerx Pharma are expected to grow in the coming year, from ($0.62) to ($0.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vincerx Pharma is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vincerx Pharma is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVincerx Pharma has a P/B Ratio of 1.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Vincerx Pharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Chaikin Analytics50-year Wall Street Legend Issues July Stock WarningJuly is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks – including NVDA – stumbling?To see this July stock warning for yourself – 100% free – click here. About Vincerx Pharma Stock (NASDAQ:VINC)Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.Read More VINC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VINC Stock News HeadlinesMay 15, 2024 | msn.comVincerx Pharma GAAP EPS of -$0.58May 15, 2024 | finanznachrichten.deVincerx Pharma, Inc.: Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate UpdateJuly 5, 2024 | Chaikin Analytics (Ad)50-year Wall Street Legend Issues July Stock WarningJuly is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks – including NVDA – stumbling?May 14, 2024 | investorplace.comVINC Stock Earnings: Vincerx Pharma Misses EPS for Q1 2024May 14, 2024 | globenewswire.comVincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate UpdateApril 26, 2024 | msn.comWhy Vincerx Pharma (VINC) Stock Is FallingApril 26, 2024 | globenewswire.comVincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and WarrantsApril 25, 2024 | globenewswire.comVincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and WarrantsJuly 5, 2024 | Chaikin Analytics (Ad)50-year Wall Street Legend Issues July Stock WarningJuly is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks – including NVDA – stumbling?April 23, 2024 | nasdaq.comVincerx Pharma, Inc. Common Stock (VINC)April 12, 2024 | finance.yahoo.comAgendia’s BluePrint Included in German Oncology Group GuidelinesApril 10, 2024 | finance.yahoo.comThe Rise of Zyn: The Oral Nicotine Product Going ViralApril 10, 2024 | markets.businessinsider.comVincerx Pharma Inc (VINC) Gets a Buy from Leerink PartnersApril 9, 2024 | msn.comACOR, HUBC and DATS among pre-market losersApril 9, 2024 | msn.comVincerx in selloff after early-stage data for cancer therapyApril 9, 2024 | investorplace.comWhy Is Vincerx Pharma (VINC) Stock Down 64% Today?April 8, 2024 | globenewswire.comVincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024April 2, 2024 | investorplace.comVINC Stock Earnings: Vincerx Pharma Beats EPS for Q4 2023See More Headlines Receive VINC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vincerx Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/05/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VINC CUSIPN/A CIK1796129 Webvincerapharma.com Phone650-800-6676FaxN/AEmployees42Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+566.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40,160,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-261.83% Return on Assets-145.47% Debt Debt-to-Equity RatioN/A Current Ratio0.72 Quick Ratio0.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.52 per share Price / Book1.44Miscellaneous Outstanding Shares29,530,000Free Float22,771,000Market Cap$22.15 million OptionableNot Optionable Beta1.47 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Ahmed M. Hamdy M.D. (Age 59)Co-Founder, Chairman & CEO Comp: $657.54kDr. Raquel E. Izumi Ph.D. (Age 54)Co-Founder, President, COO, Secretary & Director Comp: $591.54kMr. Alexander A. Seelenberger M.B.A. (Age 45)Chief Financial Officer Comp: $491.69kMr. Tom C. Thomas J.D. (Age 64)Founder, General Counsel & Chief Legal Officer Comp: $444.14kDr. John C. Byrd M.D.Founder & Chairman of Scientific Advisory BoardDr. Hans-Georg Lerchen Ph.D.Chief Scientific OfficerMs. Gabriela JairalaSr Executive Director of Investor Relations & Corporate CommunicationsMs. Karen QuarfordVice President of Quality Operations & ComplianceMs. Melissa Merrick SPHRSenior Director of People & Culture and Head of Human ResourceDr. Beatrix Stelte-Ludwig Ph.D.Executive Chief Development OfficerMore ExecutivesKey CompetitorsCellectar BiosciencesNASDAQ:CLRBEton PharmaceuticalsNASDAQ:ETONBenitec BiopharmaNASDAQ:BNTCAclaris TherapeuticsNASDAQ:ACRSPMV PharmaceuticalsNASDAQ:PMVPView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 153,575 shares on 5/10/2024Ownership: 3.115%Acadian Asset Management LLCSold 36,571 shares on 5/10/2024Ownership: 0.025%Alexander A SeelenbergerBought 10,500 shares on 8/11/2023Total: $9,975.00 ($0.95/share)Ahmed Md HamdyBought 16,900 shares on 8/9/2023Total: $16,055.00 ($0.95/share)View All Insider TransactionsView All Institutional Transactions VINC Stock Analysis - Frequently Asked Questions How have VINC shares performed this year? Vincerx Pharma's stock was trading at $1.18 at the beginning of the year. Since then, VINC stock has decreased by 38.6% and is now trading at $0.7250. View the best growth stocks for 2024 here. How were Vincerx Pharma's earnings last quarter? Vincerx Pharma, Inc. (NASDAQ:VINC) issued its quarterly earnings results on Tuesday, May, 14th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by $0.08. How do I buy shares of Vincerx Pharma? Shares of VINC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VINC) was last updated on 7/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | Sponsored50-year Wall Street Legend: “Prepare for a cash avalanche”The Dow crossed 40,000 for the first time in history… The S&P has hit over 30 all-time highs since the star...Chaikin Analytics | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | SponsoredNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredGrab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vincerx Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vincerx Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VINC Stock Alerts